Posted by Michael Wonder on 14 Oct 2022
Outcomes from the September 2022 PBAC intracycle meeting
14 October 2022 - The recommendations made by the PBAC in September 2022 relating to the listing of medicines on the PBS are now available.
For those with a keen eye, the PBAC also made a recommendation for the listing of a vaccine on the NIP.
The PBAC recommended the PBS/NIP listing of:
- Azacitidine (Onureg) - acute myeloid leukaemia
- Cannabidiol (Epidyolex) - epilepsy (Lennox-Gastaut syndrome)
- Influenza vaccine (quadrivalent, adjuvanted) (Flucelvax Quad) - vaccination for the prevention of influenza
The PBAC rejected the listing of ruxolitinib phosphate (Jakavi) for patients with chronic graft versus host disease and tixagevimab and cilgavimab (Evusheld) for the pre-exposure prevention of COVID 19.
The PBAC deferred the listing of vosoritide for patients with achondroplasia - a further price reduction is required.
The submission for cannabidiol was not listed in the published agenda.
All of these outcomes have been entered in the MAESTrO Database.
